Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte Corporation's Oral JAK1 Inhibitor in Patients With Chronic Plaque Psoriasis
Published: Oct 03, 2013
ISTANBUL--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced results from a 28-day, placebo-controlled, dose-escalation Phase II proof-of-concept clinical trial involving 50 patients with chronic plaque psoriasis for its proprietary oral JAK1 inhibitor, INCB39110. The results were presented by Robert Bissonnette, M.D., President of Innovaderm Research Inc. and co-lead investigator, today at the European Academy of Dermatology and Venereology (EADV) Congress in Istanbul, Turkey.
Help employers find you! Check out all the jobs and post your resume.